Trials / Terminated
TerminatedNCT04614025
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Pluristem Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PLX-PAD | PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells |
Timeline
- Start date
- 2020-10-19
- Primary completion
- 2021-08-04
- Completion
- 2023-02-07
- First posted
- 2020-11-03
- Last updated
- 2024-08-29
Locations
9 sites across 2 countries: Germany, Israel
Source: ClinicalTrials.gov record NCT04614025. Inclusion in this directory is not an endorsement.